Combined Use of the Adenosine A2A Antagonist KW-6002 with l-DOPA or with Selective D1 or D2 Dopamine Agonists Increases Antiparkinsonian Activity but Not Dyskinesia in MPTP-Treated Monkeys

References

Page 1

	Year	Citations
Biochemical pathophysiology of Parkinson's disease. O Hornykiewicz, Stephen J. Kish PubMed Neurodegenerative DiseasesBiochemical PathophysiologyParkinson DiseaseNeurologyNeuroscience	1987	852
Characterization of the A2 adenosine receptor labeled by [3H]NECA in rat striatal membranes. Robert F. Bruns, Gina H. Lu, Thomas A. Pugsley Molecular Pharmacology	1986	832
Striatal Restricted Adenosine A<sub>2</sub> Receptor (RDC8) Is Expressed by Enkephalin but Not by Substance P Neurons: An In Situ Hybridization Histochemistry Study Serge N. Schiffmann, O. E. Jacobs, Jean‐Jacques Vanderhaeghen Journal of Neurochemistry	1991	529
Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease Leonard Verhagen Metman, Paolo Del Dotto, Pepijn van den Munckhof, Neurology	1998	511
Subclasses of adenosine receptors in the central nervous system: Interaction with caffeine and related methylxanthines John W. Daly, Pamela Butts-Lamb, William L. Padgett Cellular and Molecular Neurobiology Adenosine ReceptorsNeurophysiologyMedicinePhysiologyAnesthetic Mechanism	1983	443
Adenosine A<sub>2A</sub> Antagonist: A novel antiparkinsonian agent that does not provoke dyskinesia in Parkinsonian monkeys Tomoyuki Kanda, Michael Jackson, Lance A. Smith, Annals of Neurology	1998	356
Direct autoradiographic localization of adenosine A2 receptors in the rat brain using the A2-selective agonist, [3H]CGS 21680 Michael F. Jarvis, Michael Williams European Journal of Pharmacology A2-selective AgonistNeurophysiologyAdenosine A2 ReceptorsSynaptic TransmissionPhysiology	1989	339
Entacapone improves motor fluctuations in levodopa‐ treated Parkinson's disease patients Annals of Neurology	1997	306
Overview of morphological changes in Parkinson's disease. K. A. Jellinger PubMed Neurodegenerative DiseasesMorphological ChangesNeurobiology Of DiseaseNeurological DisorderNeuroanatomy	1987	271
Chronic <scp>L</scp>‐DOPA administration induces dyskinesias in the 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine‐treated common marmoset (<i>Callithrix jacchus</i>) R. K. B. Pearce, Michael S. Jackson, L. A. Smith, Movement Disorders	1995	217

Page 1